SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: michael97123 who wrote (5795)3/4/2002 5:10:49 PM
From: Biomaven  Respond to of 52153
 
mike,

<MEDI>

MEDI has actually done pretty well compared with most biotechs of late. The near-term driver is likely to be whether or not they can get approval for AVIR's nasal 'flu vaccine for the upcoming season. If they do, the stock should do well. They also have an excellent entrant in the psoriasis stakes via MEDI-507, although BTRN is probably a purer play on this.

I have some MEDI that I got in the AVIR acquisition that I'm hanging onto.

Peter